"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".

JSON

Rasmussen B, Göhring G, Bernard E, Nilsson L, Tobiasson M, Jädersten M, Garelius H, Dybedal I, Grønbaek K, Ejerblad E, Lorenz F, Flogegård M, Marcher CW, Öster Fernström A, Cavelier L, Papaemmanuil E, Ebeling F, Kittang AO, Nørgaard JM, Saft L, Möllgård L, Hellström-Lindberg E

Leukemia 36 (5) 1436-1439 [2022-05-00; online 2022-03-11]

Clinical Genomics Uppsala [Collaborative]

PubMed 35277655

DOI 10.1038/s41375-022-01537-w

Crossref 10.1038/s41375-022-01537-w

pmc: PMC9061286
pii: 10.1038/s41375-022-01537-w